Coronary disease & ACSCohort study
Diabetic Status and Thrombogenicity
- Prospective registry cohort study
Authors' conclusion
In percutaneous coronary intervention-treated patients, diabetic status and clot-strength value were significantly correlated. High clot-strength phenotype increased the risk for MACE, irrespective of diabetic phenotype.
Study context
- Population
- Patients with CAD undergoing PCI, with on-admission glycated hemoglobin and thromboelastography thrombogenicity indexes
- Participants
- 2,501 patients
- Exposure
- Diabetes mellitus (DM) vs no DM
- DMn = 970
- Outcome
- Major adverse cardiovascular events (MACE):
- All-cause death
- MI
- Stroke
- Follow-up
- 4-year follow-up
Main finding
As reported in the abstract
Thrombogenicity (thromboelastography)
| Group | Platelet-fibrin clot strength (PFCS), maximal amplitude, median [Q1-Q3] | Lysis at 30 min, median [Q1-Q3] |
|---|---|---|
| DM | 67.1 [62.2-72.2] mm | 0.1% [0.0%-1.0%] |
| No DM | 65.5 [61.0-70.4] mm | 0.2% [0.0%-1.3%] |
- DM vs No DM: P < 0.001 — PFCS (maximal amplitude)
- DM vs No DM: P = 0.003 — lysis at 30 min
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| MACE (multivariable analysis) · 4-year follow-up — DM phenotype vs No DM · independently associated with MACE | 1.38 (1.05–1.79) | P = 0.018 | |
| MACE (multivariable analysis) · 4-year follow-up — Diabetic phenotype and high PFCS vs No DM · additive effect on MACE | 2.49 (1.77–3.51) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
PFCS vs glycated hemoglobin
- Positive relationship with glycated hemoglobin up to 7.0%, then plateau
Original publication
Diabetic Status and Thrombogenicity. JACC Cardiovasc Interv. Published 24 March 2025. doi:10.1016/j.jcin.2024.12.002
Summarised from the published abstract; every number is checked against it